"Watching time tick by...": Decision making for Duchenne muscular dystrophy trials

Holly L. Peay, Hadar Scharff, Aad Tibben, Benjamin Wilfond, Janice Bowie, Joanna Johnson, Kanneboyina Nagaraju, Diana Escolar, Jonathan Piacentino, Barbara B. Biesecker

Research output: Contribution to journalArticle

Abstract

Objective: This interview study explored clinicians' perspectives and parents' decision making about children's participation in Duchenne muscular dystrophy (DMD) clinical trials. Methods: Data from semi-structured interviews conducted with clinicians and parents in U.S. or Canada were assessed using thematic analysis. Results: Eleven clinicians involved in ten trials and fifteen parents involved in six trials were interviewed. Parents described benefit-risk assessments using information from advocacy, peers, professionals, and sponsors. Strong influence was attributed to the progressive nature of DMD. Most expected direct benefit. Few considered the possibility of trial failure. Most made decisions to participate before the informed consent (IC) process, but none-the-less perceived informed choice with little to lose for potential gain.Clinicians described more influence on parental decisions than attributed by parents. Clinicians felt responsible to facilitate IC while maintaining hope. Both clinicians and parents reported criticisms about the IC process and regulatory barriers. Conclusions: The majority of parents described undertaking benefit-risk assessments that led to informed choices that offered psychological and potential disease benefits. Parents' high expectations influenced their decisions while also reflecting optimism. Clinicians felt challenged in balancing parents' expectations and likely outcomes. Prognosis-related pressures coupled with decision making prior to IC suggest an obligation to ensure educational materials are understandable and accurate, and to consider an expanded notion of IC timeframes. Anticipatory guidance about potential trial failure might facilitate parents' deliberations while aiding clinicians in moderating overly-optimistic motivations. Regulators and industry should appreciate special challenges in progressive disorders, where doing nothing was equated with doing harm.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalContemporary Clinical Trials
Volume46
DOIs
StatePublished - Jan 1 2016

Fingerprint

Duchenne Muscular Dystrophy
Ticks
Decision Making
Parents
Informed Consent
Hope
Interviews
Canada
Motivation
Industry
Clinical Trials
Psychology
Pressure

Keywords

  • Clinical trial
  • Consent
  • Duchenne muscular dystrophy
  • Proxy decision making

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

"Watching time tick by..." : Decision making for Duchenne muscular dystrophy trials. / Peay, Holly L.; Scharff, Hadar; Tibben, Aad; Wilfond, Benjamin; Bowie, Janice; Johnson, Joanna; Nagaraju, Kanneboyina; Escolar, Diana; Piacentino, Jonathan; Biesecker, Barbara B.

In: Contemporary Clinical Trials, Vol. 46, 01.01.2016, p. 1-6.

Research output: Contribution to journalArticle

Peay, HL, Scharff, H, Tibben, A, Wilfond, B, Bowie, J, Johnson, J, Nagaraju, K, Escolar, D, Piacentino, J & Biesecker, BB 2016, '"Watching time tick by...": Decision making for Duchenne muscular dystrophy trials', Contemporary Clinical Trials, vol. 46, pp. 1-6. https://doi.org/10.1016/j.cct.2015.11.006
Peay, Holly L. ; Scharff, Hadar ; Tibben, Aad ; Wilfond, Benjamin ; Bowie, Janice ; Johnson, Joanna ; Nagaraju, Kanneboyina ; Escolar, Diana ; Piacentino, Jonathan ; Biesecker, Barbara B. / "Watching time tick by..." : Decision making for Duchenne muscular dystrophy trials. In: Contemporary Clinical Trials. 2016 ; Vol. 46. pp. 1-6.
@article{16c1d44da2674a6eaa12ff14fcc6b91b,
title = "{"}Watching time tick by...{"}: Decision making for Duchenne muscular dystrophy trials",
abstract = "Objective: This interview study explored clinicians' perspectives and parents' decision making about children's participation in Duchenne muscular dystrophy (DMD) clinical trials. Methods: Data from semi-structured interviews conducted with clinicians and parents in U.S. or Canada were assessed using thematic analysis. Results: Eleven clinicians involved in ten trials and fifteen parents involved in six trials were interviewed. Parents described benefit-risk assessments using information from advocacy, peers, professionals, and sponsors. Strong influence was attributed to the progressive nature of DMD. Most expected direct benefit. Few considered the possibility of trial failure. Most made decisions to participate before the informed consent (IC) process, but none-the-less perceived informed choice with little to lose for potential gain.Clinicians described more influence on parental decisions than attributed by parents. Clinicians felt responsible to facilitate IC while maintaining hope. Both clinicians and parents reported criticisms about the IC process and regulatory barriers. Conclusions: The majority of parents described undertaking benefit-risk assessments that led to informed choices that offered psychological and potential disease benefits. Parents' high expectations influenced their decisions while also reflecting optimism. Clinicians felt challenged in balancing parents' expectations and likely outcomes. Prognosis-related pressures coupled with decision making prior to IC suggest an obligation to ensure educational materials are understandable and accurate, and to consider an expanded notion of IC timeframes. Anticipatory guidance about potential trial failure might facilitate parents' deliberations while aiding clinicians in moderating overly-optimistic motivations. Regulators and industry should appreciate special challenges in progressive disorders, where doing nothing was equated with doing harm.",
keywords = "Clinical trial, Consent, Duchenne muscular dystrophy, Proxy decision making",
author = "Peay, {Holly L.} and Hadar Scharff and Aad Tibben and Benjamin Wilfond and Janice Bowie and Joanna Johnson and Kanneboyina Nagaraju and Diana Escolar and Jonathan Piacentino and Biesecker, {Barbara B.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.cct.2015.11.006",
language = "English (US)",
volume = "46",
pages = "1--6",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - "Watching time tick by..."

T2 - Decision making for Duchenne muscular dystrophy trials

AU - Peay, Holly L.

AU - Scharff, Hadar

AU - Tibben, Aad

AU - Wilfond, Benjamin

AU - Bowie, Janice

AU - Johnson, Joanna

AU - Nagaraju, Kanneboyina

AU - Escolar, Diana

AU - Piacentino, Jonathan

AU - Biesecker, Barbara B.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective: This interview study explored clinicians' perspectives and parents' decision making about children's participation in Duchenne muscular dystrophy (DMD) clinical trials. Methods: Data from semi-structured interviews conducted with clinicians and parents in U.S. or Canada were assessed using thematic analysis. Results: Eleven clinicians involved in ten trials and fifteen parents involved in six trials were interviewed. Parents described benefit-risk assessments using information from advocacy, peers, professionals, and sponsors. Strong influence was attributed to the progressive nature of DMD. Most expected direct benefit. Few considered the possibility of trial failure. Most made decisions to participate before the informed consent (IC) process, but none-the-less perceived informed choice with little to lose for potential gain.Clinicians described more influence on parental decisions than attributed by parents. Clinicians felt responsible to facilitate IC while maintaining hope. Both clinicians and parents reported criticisms about the IC process and regulatory barriers. Conclusions: The majority of parents described undertaking benefit-risk assessments that led to informed choices that offered psychological and potential disease benefits. Parents' high expectations influenced their decisions while also reflecting optimism. Clinicians felt challenged in balancing parents' expectations and likely outcomes. Prognosis-related pressures coupled with decision making prior to IC suggest an obligation to ensure educational materials are understandable and accurate, and to consider an expanded notion of IC timeframes. Anticipatory guidance about potential trial failure might facilitate parents' deliberations while aiding clinicians in moderating overly-optimistic motivations. Regulators and industry should appreciate special challenges in progressive disorders, where doing nothing was equated with doing harm.

AB - Objective: This interview study explored clinicians' perspectives and parents' decision making about children's participation in Duchenne muscular dystrophy (DMD) clinical trials. Methods: Data from semi-structured interviews conducted with clinicians and parents in U.S. or Canada were assessed using thematic analysis. Results: Eleven clinicians involved in ten trials and fifteen parents involved in six trials were interviewed. Parents described benefit-risk assessments using information from advocacy, peers, professionals, and sponsors. Strong influence was attributed to the progressive nature of DMD. Most expected direct benefit. Few considered the possibility of trial failure. Most made decisions to participate before the informed consent (IC) process, but none-the-less perceived informed choice with little to lose for potential gain.Clinicians described more influence on parental decisions than attributed by parents. Clinicians felt responsible to facilitate IC while maintaining hope. Both clinicians and parents reported criticisms about the IC process and regulatory barriers. Conclusions: The majority of parents described undertaking benefit-risk assessments that led to informed choices that offered psychological and potential disease benefits. Parents' high expectations influenced their decisions while also reflecting optimism. Clinicians felt challenged in balancing parents' expectations and likely outcomes. Prognosis-related pressures coupled with decision making prior to IC suggest an obligation to ensure educational materials are understandable and accurate, and to consider an expanded notion of IC timeframes. Anticipatory guidance about potential trial failure might facilitate parents' deliberations while aiding clinicians in moderating overly-optimistic motivations. Regulators and industry should appreciate special challenges in progressive disorders, where doing nothing was equated with doing harm.

KW - Clinical trial

KW - Consent

KW - Duchenne muscular dystrophy

KW - Proxy decision making

UR - http://www.scopus.com/inward/record.url?scp=84946882050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946882050&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2015.11.006

DO - 10.1016/j.cct.2015.11.006

M3 - Article

C2 - 26546066

AN - SCOPUS:84946882050

VL - 46

SP - 1

EP - 6

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

ER -